Have a feature idea you'd love to see implemented?
Let us know!
NBIX Neurocrine Biosciences Inc
Price (delayed)
$135.42
Market cap
$13.71B
P/E Ratio
35.08
Dividend/share
N/A
EPS
$3.86
Enterprise value
$13.61B
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological
Highlights
The company's net income has surged by 102% YoY and by 14% QoQ
NBIX's EPS has surged by 97% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of NBIX
Market
Valuations
Earnings
Shares outstanding
101.25M
Market cap
$13.71B
Enterprise value
$13.61B
Price to earnings (P/E)
35.08
Price to book (P/B)
5.03
Price to sales (P/S)
6.1
EV/EBIT
25.99
EV/EBITDA
24.77
EV/Sales
6.07
Revenue
$2.24B
Gross profit
$2.21B
Net income
$385.9M
EBIT
$523.8M
EBITDA
$549.5M
Free cash flow
$440.1M
Per share
Balance sheet
Liquidity
EPS
$3.86
EPS diluted
$3.75
Free cash flow per share
$4.35
Book value per share
$26.93
Revenue per share
$22.18
TBVPS
$34.62
Total assets
$3.54B
Total liabilities
$816.1M
Debt
$251.4M
Equity
$2.72B
Working capital
$1.45B
Debt to equity
0.09
Current ratio
4.37
Quick ratio
3.98
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
24.5%
Gross margin
98.5%
Net margin
17.2%
Operating margin
25.8%
Return on assets
11.4%
Return on equity
15.7%
Return on invested capital
18.2%
Return on capital employed
16.9%
Return on sales
23.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NBIX stock price
How has the Neurocrine Biosciences stock price performed over time
Intraday
0.34%
1 week
6.88%
1 month
9.84%
1 year
12.56%
YTD
2.78%
QTD
17.53%
Financial performance
How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$2.24B
Gross profit
$2.21B
Operating income
$578.8M
Net income
$385.9M
Gross margin
98.5%
Net margin
17.2%
The operating income has surged by 184% year-on-year and by 8% since the previous quarter
The operating margin has soared by 126% YoY
The company's net income has surged by 102% YoY and by 14% QoQ
The net margin has soared by 61% YoY and by 8% QoQ
Growth
What is Neurocrine Biosciences's growth rate over time
Valuation
What is Neurocrine Biosciences stock price valuation
P/E
35.08
P/B
5.03
P/S
6.1
EV/EBIT
25.99
EV/EBITDA
24.77
EV/Sales
6.07
NBIX's EPS has surged by 97% year-on-year and by 13% since the previous quarter
The price to earnings (P/E) is 68% lower than the 5-year quarterly average of 109.1 and 11% lower than the last 4 quarters average of 39.5
The company's equity rose by 36% YoY and by 8% QoQ
NBIX's price to book (P/B) is 33% lower than its 5-year quarterly average of 7.5 and 5% lower than its last 4 quarters average of 5.3
Neurocrine Biosciences's revenue has increased by 26% YoY and by 6% QoQ
The stock's price to sales (P/S) is 22% less than its 5-year quarterly average of 7.8 and 4.7% less than its last 4 quarters average of 6.4
Efficiency
How efficient is Neurocrine Biosciences business performance
NBIX's return on sales has surged by 65% year-on-year and by 10% since the previous quarter
Neurocrine Biosciences's return on assets has surged by 52% YoY and by 9% QoQ
The ROE has grown by 50% YoY and by 5% from the previous quarter
The company's return on invested capital rose by 44% YoY and by 8% QoQ
Dividends
What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NBIX.
Financial health
How did Neurocrine Biosciences financials performed over time
The company's current ratio has surged by 83% YoY and by 4.3% QoQ
Neurocrine Biosciences's quick ratio has soared by 82% YoY and by 5% from the previous quarter
The debt is 91% lower than the equity
The company's equity rose by 36% YoY and by 8% QoQ
NBIX's debt to equity is down by 31% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.